INDIVIOR PHARMACEUTICALS INC (INDV) Fundamental Analysis & Valuation

NASDAQ:INDV • US45579U1097

Current stock price

37.66 USD
+0.88 (+2.39%)
At close:
37.66 USD
0 (0%)
After Hours:

This INDV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. INDV Profitability Analysis

1.1 Basic Checks

  • In the past year INDV was profitable.
  • In the past year INDV has reported a negative cash flow from operations.
  • The reported net income has been mixed in the past 5 years: INDV reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: INDV reported negative operating cash flow in multiple years.
INDV Yearly Net Income VS EBIT VS OCF VS FCFINDV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 17.32%, INDV belongs to the top of the industry, outperforming 94.76% of the companies in the same industry.
  • INDV has a better Return On Invested Capital (72.94%) than 100.00% of its industry peers.
  • INDV had an Average Return On Invested Capital over the past 3 years of 64.11%. This is significantly above the industry average of 13.59%.
  • The 3 year average ROIC (64.11%) for INDV is below the current ROIC(72.94%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 17.32%
ROE N/A
ROIC 72.94%
ROA(3y)3.44%
ROA(5y)3.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)64.11%
ROIC(5y)46.29%
INDV Yearly ROA, ROE, ROICINDV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400

1.3 Margins

  • INDV has a Profit Margin of 16.77%. This is amongst the best in the industry. INDV outperforms 87.96% of its industry peers.
  • INDV has a better Operating Margin (21.37%) than 88.48% of its industry peers.
  • In the last couple of years the Operating Margin of INDV has grown nicely.
  • INDV has a better Gross Margin (80.16%) than 85.34% of its industry peers.
  • INDV's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 21.37%
PM (TTM) 16.77%
GM 80.16%
OM growth 3Y1.1%
OM growth 5Y13.25%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.08%
GM growth 5Y-0.39%
INDV Yearly Profit, Operating, Gross MarginsINDV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. INDV Health Analysis

2.1 Basic Checks

  • INDV has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for INDV remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for INDV has been reduced compared to 5 years ago.
  • INDV has a worse debt/assets ratio than last year.
INDV Yearly Shares OutstandingINDV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
INDV Yearly Total Debt VS Total AssetsINDV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 3.34 indicates that INDV is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 3.34, INDV is in the better half of the industry, outperforming 64.40% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 3.34
ROIC/WACC7.61
WACC9.58%
INDV Yearly LT Debt VS Equity VS FCFINDV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 0.71 indicates that INDV may have some problems paying its short term obligations.
  • INDV's Current ratio of 0.71 is on the low side compared to the rest of the industry. INDV is outperformed by 91.62% of its industry peers.
  • INDV has a Quick Ratio of 0.71. This is a bad value and indicates that INDV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • INDV has a worse Quick ratio (0.55) than 91.10% of its industry peers.
Industry RankSector Rank
Current Ratio 0.71
Quick Ratio 0.55
INDV Yearly Current Assets VS Current LiabilitesINDV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. INDV Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 527.08% over the past year.
  • The Revenue has been growing slightly by 4.29% in the past year.
  • Measured over the past years, INDV shows a quite strong growth in Revenue. The Revenue has been growing by 13.88% on average per year.
EPS 1Y (TTM)527.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%134.15%
Revenue 1Y (TTM)4.29%
Revenue growth 3Y11.2%
Revenue growth 5Y13.88%
Sales Q2Q%19.17%

3.2 Future

  • The Earnings Per Share is expected to grow by 9.40% on average over the next years. This is quite good.
  • Based on estimates for the next years, INDV will show a small growth in Revenue. The Revenue will grow by 2.98% on average per year.
EPS Next Y27.98%
EPS Next 2Y19.17%
EPS Next 3Y16.42%
EPS Next 5Y9.4%
Revenue Next Year-2.63%
Revenue Next 2Y1.23%
Revenue Next 3Y3.01%
Revenue Next 5Y2.98%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
INDV Yearly Revenue VS EstimatesINDV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B
INDV Yearly EPS VS EstimatesINDV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

6

4. INDV Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 12.51, the valuation of INDV can be described as correct.
  • Compared to the rest of the industry, the Price/Earnings ratio of INDV indicates a rather cheap valuation: INDV is cheaper than 87.96% of the companies listed in the same industry.
  • INDV is valuated cheaply when we compare the Price/Earnings ratio to 26.51, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 10.78 indicates a reasonable valuation of INDV.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of INDV indicates a rather cheap valuation: INDV is cheaper than 85.86% of the companies listed in the same industry.
  • INDV is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 21.41, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 12.51
Fwd PE 10.78
INDV Price Earnings VS Forward Price EarningsINDV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, INDV is valued cheaper than 81.15% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 17.15
INDV Per share dataINDV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of INDV may justify a higher PE ratio.
  • INDV's earnings are expected to grow with 16.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.45
PEG (5Y)N/A
EPS Next 2Y19.17%
EPS Next 3Y16.42%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. INDV Dividend Analysis

5.1 Amount

  • INDV does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INDV Fundamentals: All Metrics, Ratios and Statistics

INDIVIOR PHARMACEUTICALS INC

NASDAQ:INDV (5/1/2026, 8:00:02 PM)

After market: 37.66 0 (0%)

37.66

+0.88 (+2.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength67.7
Industry Growth15.53
Earnings (Last)04-30
Earnings (Next)07-29
Inst Owners90.94%
Inst Owner Change0.7%
Ins Owners3.95%
Ins Owner Change39.75%
Market Cap4.59B
Revenue(TTM)1.24B
Net Income(TTM)208.00M
Analysts84.62
Price Target49.13 (30.46%)
Short Float %11.93%
Short Ratio5.38
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)45.37%
Min EPS beat(2)19.28%
Max EPS beat(2)71.47%
EPS beat(4)4
Avg EPS beat(4)63.83%
Min EPS beat(4)19.28%
Max EPS beat(4)92.31%
EPS beat(8)6
Avg EPS beat(8)8.23%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)16.19%
Min Revenue beat(2)14.84%
Max Revenue beat(2)17.53%
Revenue beat(4)4
Avg Revenue beat(4)15.52%
Min Revenue beat(4)8.6%
Max Revenue beat(4)21.1%
Revenue beat(8)5
Avg Revenue beat(8)8.03%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.79%
PT rev (3m)12.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.6%
EPS NY rev (1m)2.16%
EPS NY rev (3m)6.59%
Revenue NQ rev (1m)0.08%
Revenue NQ rev (3m)0.71%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.28%
Valuation
Industry RankSector Rank
PE 12.51
Fwd PE 10.78
P/S 3.7
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 17.15
EPS(TTM)3.01
EY7.99%
EPS(NY)3.49
Fwd EY9.28%
FCF(TTM)-0.77
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS10.17
BVpS-0.8
TBVpS-0.82
PEG (NY)0.45
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA 17.32%
ROE N/A
ROCE 92.33%
ROIC 72.94%
ROICexc 227.55%
ROICexgc 232.61%
OM 21.37%
PM (TTM) 16.77%
GM 80.16%
FCFM N/A
ROA(3y)3.44%
ROA(5y)3.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)64.11%
ROIC(5y)46.29%
ROICexc(3y)336.53%
ROICexc(5y)N/A
ROICexgc(3y)385.91%
ROICexgc(5y)N/A
ROCE(3y)81.15%
ROCE(5y)58.59%
ROICexgc growth 3YN/A
ROICexgc growth 5Y-13.81%
ROICexc growth 3YN/A
ROICexc growth 5Y23.47%
OM growth 3Y1.1%
OM growth 5Y13.25%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.08%
GM growth 5Y-0.39%
F-Score4
Asset Turnover1.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 1.05
Cap/Depr 670%
Cap/Sales 5.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.71
Quick Ratio 0.55
Altman-Z 3.34
F-Score4
WACC9.58%
ROIC/WACC7.61
Cap/Depr(3y)376.74%
Cap/Depr(5y)263.21%
Cap/Sales(3y)4.29%
Cap/Sales(5y)3.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)527.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%134.15%
EPS Next Y27.98%
EPS Next 2Y19.17%
EPS Next 3Y16.42%
EPS Next 5Y9.4%
Revenue 1Y (TTM)4.29%
Revenue growth 3Y11.2%
Revenue growth 5Y13.88%
Sales Q2Q%19.17%
Revenue Next Year-2.63%
Revenue Next 2Y1.23%
Revenue Next 3Y3.01%
Revenue Next 5Y2.98%
EBIT growth 1Y-10.47%
EBIT growth 3Y12.42%
EBIT growth 5Y28.97%
EBIT Next Year40.99%
EBIT Next 3Y17.86%
EBIT Next 5Y3.38%
FCF growth 1Y-1980%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-175%
OCF growth 3YN/A
OCF growth 5YN/A

INDIVIOR PHARMACEUTICALS INC / INDV Fundamental Analysis FAQ

What is the fundamental rating for INDV stock?

ChartMill assigns a fundamental rating of 5 / 10 to INDV.


What is the valuation status for INDV stock?

ChartMill assigns a valuation rating of 8 / 10 to INDIVIOR PHARMACEUTICALS INC (INDV). This can be considered as Undervalued.


How profitable is INDIVIOR PHARMACEUTICALS INC (INDV) stock?

INDIVIOR PHARMACEUTICALS INC (INDV) has a profitability rating of 7 / 10.


Can you provide the financial health for INDV stock?

The financial health rating of INDIVIOR PHARMACEUTICALS INC (INDV) is 4 / 10.


What is the expected EPS growth for INDIVIOR PHARMACEUTICALS INC (INDV) stock?

The Earnings per Share (EPS) of INDIVIOR PHARMACEUTICALS INC (INDV) is expected to grow by 27.98% in the next year.